Results 81 to 90 of about 3,401,781 (173)

Artesunate may attenuate the effects of Cytokine Release Syndrome (CRS) in Covid-19 Disease by targeting Interleukin-6 and associated inflammatory response pathways

open access: yes, 2020
The coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an unprecedented global health challenge for which safe, effective and affordable treatments need to be rapidly ...
Sanjeev Krishna   +3 more
core   +1 more source

Severe Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis (HLH)-Like Syndrome Following Administration of Combined Brentuximab Vedotin and Nivolumab for Recurrent Classical Hodgkin Lymphoma: A Case Report

open access: yes
Osama Mosalem,1 Tanmayi Pai,1 Mohammed Alqawasma,2 Marwan Shaikh,1 K David Li,3 Muhamad Alhaj Moustafa1 1Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA; 2Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Jacksonville ...
Li KD   +5 more
core  

Additional file 6: of A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

open access: yes, 2018
Interleukin-6 levels by cytokine release syndrome grade. Peak IL-6 levels by CRS grade.
Liu-Fang Gu (6109343)   +28 more
core   +1 more source

DataSheet_2_Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model.xlsx

open access: yes
ObjectivesDespite their efficacy, some immunotherapies have been shown to induce immune-related adverse events, including the potentially life-threatening cytokine release syndrome (CRS), calling for reliable and translational preclinical models to ...
Florence Renart-Depontieu (15149832)   +13 more
core   +1 more source

Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model

open access: yesFrontiers in Immunology
ObjectivesDespite their efficacy, some immunotherapies have been shown to induce immune-related adverse events, including the potentially life-threatening cytokine release syndrome (CRS), calling for reliable and translational preclinical models to ...
Gaëlle H. Martin   +13 more
doaj   +1 more source

DataSheet_1_Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model.docx

open access: yes
ObjectivesDespite their efficacy, some immunotherapies have been shown to induce immune-related adverse events, including the potentially life-threatening cytokine release syndrome (CRS), calling for reliable and translational preclinical models to ...
Florence Renart-Depontieu (15149832)   +13 more
core   +1 more source

Utilizing plasma exchange for severe cytokine release syndrome after CAR-T cell therapy: clinical experience and literature insights

open access: yesFrontiers in Immunology
Cytokine release syndrome (CRS) is a severe complication following Chimeric Antigen Receptor T-cell (CAR-T) therapy, characterized by an excessive inflammatory response triggered by the activation of CAR-T cells.
Jiasi Zhang   +9 more
doaj   +1 more source

Cytokine release syndrome in non- small cell lung cancer patient receiving immune checkpoint inhibitors: A case report

open access: yesCurrent Problems in Cancer: Case Reports
Cytokine release syndrome (CRS) is a well-described immune-related adverse event following chimeric antigen receptor T-cell therapy (CAR-T) but has rarely been reported following therapy with immune checkpoint inhibitors (ICI).We present a clinical case ...
Ana Geltar, Assist Urska Janzic
doaj   +1 more source

Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report [PDF]

open access: yes
Chimeric Antigen Receptor T (CAR-T) cell therapy significantly and rapidly changed the treatment paradigm for lymphoma, myeloma and leukemia, and the recent approvals of the first cellular immunotherapies in melanoma and synovial sarcoma demonstrate the ...
Tyler Ruemmele   +6 more
core   +1 more source

Diagnosis and Treatment of Epstein-Barr Virus-Positive Diffuse Large B-cell Lymphoma Complicated by Cytokine Release Syndrome

open access: yesXiehe Yixue Zazhi
Epstein-Barr virus-positive diffuse large B-cell lymphoma, not otherwise specified(EBV+DLBCL, NOS) is a lymphoma subtype characterized by distinct biological features and a poor prognosis.
KONG Qi, MA Ji, GUO Zhijun
doaj   +1 more source

Home - About - Disclaimer - Privacy